<DOC>
	<DOCNO>NCT02517593</DOCNO>
	<brief_summary>The primary aim study determine addition individual polygenic risk score ( PRS ) , addition standard National Cancer Institute 's Breast Cancer Risk Assessment Tool ( BCRAT ) Tyrer-Cuzick ( IBIS ) score , aid woman risk breast cancer make decision take ( take ) medication prevent breast cancer</brief_summary>
	<brief_title>Genetic Risk Estimation Breast Cancer Prior Preventive Medication Uptake</brief_title>
	<detailed_description>This trial prospective pilot study look integrate novel retrospectively validate polygenic risk score ( PRS ) , base 77 Single Nucleotide Polymorphisms ( SNPs ) , standard breast cancer prevention consultation non-BRCA woman . In order eligible trial participation , woman need BCRAT estimate ≥3 % 5 year risk develop breast cancer ( corresponds United States Preventative Services Task Force threshold moderate strong benefit breast cancer prevent medication tamoxifen raloxifene . At time breast cancer prevention consultation , woman offer participation study clinical trial nurse inform write consent obtain . For consent patient , single 7 10 ml blood sample take couriered MAYO clinic sample analysis several survey administer . One survey ass participant understanding intention take take breast cancer prevent medication . The decision take take breast cancer prevent medication defer subsequent follow visit . On second visit , PRS test result review patient recommendation regard preventive medication make . The PRS score risk stratify patient one three lifetime risk category develop breast cancer ( low risk ( &lt; 15 % lifetime risk ) , average risk ( 15 &lt; 40 % risk ) high risk ( &gt; 40 % ) ) . Participants answer second survey understand breast cancer risk intention take breast cancer prevent medication assess .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Women &gt; 35 year old &lt; 75 year old 2 . Women either follow : A. NCIBCRAT 5 year risk ≥ 3 % corresponds level moderate evidence treatment benefit outweigh risk accord US Preventative Services Task Force ( 32 ) ; B . Women IBIS ( TyrerCuzik ) score 10 year risk breast cancer ≥5 % 3 . Able participate aspect study 4 . Understand sign study inform consent 1 . Women whose BCRAT fall threshold ( &lt; 3 % 5 year risk ) moderate benefit accord US Preventative Task Force AND Women whose IBIS score &lt; 5 % 10 year risk 2 . Women know BRCA1 BRCA2 mutation 3 . Women know contraindication Tamoxifen , raloxifene exemestane 4 . Unable give inform consent 5 . Prior history invasive breast cancer ductal carcinoma situ 6 . At risk due prior radiation therapy chest</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>BCRAT</keyword>
	<keyword>IBIS</keyword>
	<keyword>PRS</keyword>
	<keyword>breast cancer</keyword>
	<keyword>Tyrer-Cuzick</keyword>
</DOC>